SCHEDULE 13G: Orca Capital AG Discloses 5.7% Stake in Pasithea Therapeutics Corp.

Orca Capital AG, a German entity, has disclosed a 5.7% beneficial ownership stake in Pasithea Therapeutics Corp., holding 371,142 shares of common stock.

Summary

• Orca Capital AG, based in Germany, has filed a Schedule 13G indicating beneficial ownership of Pasithea Therapeutics Corp. common stock.
• The filing reports that Orca Capital AG beneficially owns 371,142 shares of Pasithea Therapeutics Corp. common stock.
• This ownership represents 5.7% of the Issuer's outstanding Common Stock, calculated based on 6,529,291 shares outstanding immediately after the completion of the Issuer's registered offering.
• Orca Capital AG holds sole voting power and sole dispositive power over all 371,142 shares.
• The reporting person also holds 742,284 shares of Common Stock issuable upon the exercise of warrants, subject to a 4.99% blocker, meaning they cannot exercise warrants if it would result in beneficial ownership exceeding 4.99% of the outstanding common stock.
• The securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The disclosure of a new significant institutional investor (Orca Capital AG) taking a 5.7% stake in Pasithea Therapeutics Corp. is generally viewed favorably as it implies confidence in the company. The presence of a 4.99% blocker on warrants is a standard protective clause and does not detract significantly from the positive signal of the investment itself.

Positives

• The disclosure of a significant stake by Orca Capital AG may signal confidence from an institutional investor in Pasithea Therapeutics Corp.'s future prospects.
• The investment provides Pasithea Therapeutics Corp. with a stable, long-term shareholder base, which can be viewed positively by the market.

Negatives

• The 4.99% blocker on warrant exercise limits Orca Capital AG's ability to increase its stake beyond a certain threshold, potentially capping its influence or further investment without a different filing type.

Risks

• The 4.99% blocker on warrant exercise means Orca Capital AG cannot increase its beneficial ownership above this threshold through warrant conversion, which could limit its potential for greater influence or investment in the company's future capital raises via these specific instruments.

Future Outlook

NA

Industry Context

Pasithea Therapeutics Corp. operates in the biotechnology and pharmaceutical sector, focusing on developing treatments. The entry of a new significant institutional investor like Orca Capital AG can be seen as a vote of confidence in the company's pipeline or strategic direction within this competitive industry.

Stakeholder Impact

• Shareholders: The entry of a new significant institutional investor could be perceived positively, potentially increasing investor confidence and demand for the stock. The 4.99% blocker on warrants ensures that Orca Capital AG's ownership via these specific instruments remains below a certain threshold, which might be seen as a governance safeguard.

Key Dates

Keywords

Pasithea Therapeutics Corp., Orca Capital AG, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Warrants, Biotechnology, Pharmaceuticals